A novel option in proton pump inhibitor dosing: Lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 4, 2004, Pages 407-411

  Freston, J W ^a   Kukulka, M J ^b   Lloyd, E ^b   Lee, C ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b TAP PHARMACEUTICAL PRODUCTS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; PROTON PUMP INHIBITOR; WATER;

ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISPERSIBLE TABLET; DIZZINESS; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NASOGASTRIC TUBE; NORMAL HUMAN; PRIORITY JOURNAL; TABLET DISINTEGRATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-ULCER AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; OMEPRAZOLE; PROTON PUMPS; TABLETS;

EID: 4344638501     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02086.x     Document Type: Article

References (22)

1. Thjodleifsson B. Treatment of acid-related disorders in the elderly with emphasis on the use of proton pump inhibitors. Drugs Aging 2002; 19: 911-27.
2. Bardhan KD. Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy - a sideways glance. Yale J Biol Med 1996; 69: 211-24.
3. Chey W, Huang B, Jackson RL. Lansoprazole and esomeprazole in symptomatic GERD: a double-blind, randomised, multicentre trial in 3000 patients confirms comparable symptom relief. Clin Drug Invest 2003; 23: 69-84.
4. Howden CW, Ballard ED, Robieson W. Evidence of therapeutic equivalence of lansoprazole 30 mg and esomeprazole 40 mg in the treatment of erosive oesophagitis. Clin Drug Invest 2002; 22: 99-109.
5. Robinson M, Sahba B, Avner D, et al. Comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Aliment Pharmacol Ther 1995; 9: 25-31.
6. Jones RH, Baxter G. Lansoprazole 30 mg daily versus ranitidine 150 mg bd in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther 1998; 11: 541-6.
7. Gough AL, Long RG, Cooper BT, et al: Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996; 10: 529-39.
8. Firth M, Prather CM. Gastrointestinal motility problems in the elderly patient. Gastroenterology 2002; 122: 1688-700.
9. Wade PR. Aging and neural control of the GI tract. I. Age-related changes in the enteric nervous system. Am J Physiol Gastrointest Liver Physiol 2002; 282: G489-95.
10. Orr WC, Chen CL. Aging and neural control of the GI tract: IV. Clinical and physiological aspects of gastrointestinal motility and aging. Age-related changes in the enteric nervous system. Am J Physiol Gastrointest Liver Physiol 2002; 282: G1226-31.
11. Palmer JB, Drennan JC, Baba M. Evaluation and treatment of swallowing impairments. Am Fam Physician 2000; 61: 2453-62.
12. Lieu PK, Chong MS, Seshadri R. The impact of swallowing disorders in the elderly. Ann Acad Med Singapore 2001; 30: 148-54.
13. Thomson AB. Gastro-oesophageal reflux in the elderly: role of drug therapy in management. Drugs Aging 2001; 18: 409-14.
14. Whitaker M. Proton pump inhibitors in the elderly population. Eur J Gastroenterol Hepatol 2002; 14(Supp.1): S5-9.
15. Linder JD, Wilcox CM. Acid peptic disease in the elderly. Gastroenterol Clin North Am 2001; 30: 363-76.
16. Richter JE. Gastroesophageal reflux disease in the older patient: presentation, treatment, and complications. Am J Gastroenterol 2000; 95: 368-73.
17. Ciocon JO. Indications for tube feedings in elderly patients. Dysphagia 1990; 5: 1-5.
18. Shanley C, O'Loughlin G. Dysphagia among nursing home residents: an assessment and management protocol. J Gerontol Nurs 2000; 26: 35-48.
19. Gerloff J, Mignot A, Barth H, Heintze K. Pharmacokinetics and absolute bioavailability data of lansoprazole. Eur J Clin Pharmacol 1996; 50: 293-7.
20. Matheson AJ, Jarvis B. Lansoprazole: an update of its place in the management of acid-related disorders. Drugs 2001; 61: 1801-33.
21. Garnett WR, Garabedian-Ruffalo SM. Identification, diagnosis, and treatment of acid-related diseases in the elderly: implications for long-term care. Pharmacotherapy 1997; 17: 938-58.
22. Freston JW, Chiu Y-L, Mulford DJ, Ballard ED II. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. Ailment Pharmacol Ther 2003; 17: 361-7.